Xingrui Pharma and Pfizer Reach Exclusive Licensing Agreement with Up to $2.3 Billion in Milestone Payments
Pfizer has entered into an exclusive licensing agreement with Xingrui Pharma, granting Pfizer exclusive rights to develop, manufacture, and commercialize three in vivo chimeric antigen receptor T-cell projects that are in the pre-IND filing stage outside of Greater China. Pfizer also obtained the rights to use Xingrui Pharma's proprietary in vivo CAR-T technology in the fields of inflammatory and immune diseases and oncology, with an option to obtain exclusive licenses for candidate compounds developed in other collaborative research, which can extend to Greater China. The terms of the deal indicate that Xingrui Pharma will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in milestone payments, which are associated with specific development and commercialization milestones. Additionally, Xingrui Pharma will enjoy tiered royalties based on the net sales of approved products.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Solana 2027 Roadmap: Doubling Computing Power, Reducing Transaction Costs by 80%

UAE Expands Nighttime Oil Transport Fleet, ADNOC Becomes Key Force in Strait of Hormuz

SEC Charges Eight Entities for $37 Million Crypto Fraud Scheme

Coins.ph Restricts Users from Transferring to Self-Custody Wallets

Institutional Trading Volume on Kalshi Grows 4124% to $26.3 Billion in Six Months

Twenty One Capital Invests $10 Million to Acquire 172.25 Bitcoins

CDAI Releases White Paper on Digital Asset Talent in Hong Kong, Advocating for Improved Talent Development System

Sam Price Focuses on Ethereum Price Range

Capricor Deramiocel Application Rejected by FDA, Stock Price Falls 79% After Hours

CryptoBilis tampered Ledger devices linked to $102M in losses

Canadian Government Reaches Agreement with Union to Prevent Stellantis from Selling Ontario Plant

Ford, Honda and Others Sue New Jersey to Block Auto Repair Law Implementation

SEC freezes assets of Backward Hat Capital over 560 million dollar Ponzi scheme

BJ Wholesale Club Raises Earnings Outlook, Stock Price Drops 4.2%

Tether's Former Executives Launch Gold-Backed Token XAUt Yield Fund with a First-Year Target of Over $100 Million in Assets Under Management

Google Lowers Broadcom TPU 8i Series Shipment Forecast by About 1 Million Units for 2027

Kimberly-Clark Completes Kenvue Acquisition, Expects 2.1 Billion USD in Savings

Bubblemaps Tracks Wallets Linked to MELANIA and LIBRA, Profiting $8.4 Million

$518 Million in Bybit Hacking Transactions via Sky

New Fire Group Participates in $10 Million Cornerstone Investment in Gao Teng Bitcoin ETF

U.S. Department of Justice Reaches Settlement Agreement with Infiniweb on $225 Million USDT Forfeiture Case

BitFuFu Reports 79.1% Revenue Plunge in Q3, Net Profit at $24.9 Million

Intuit Sells Mailchimp to Bending Spoons for $3.68 Billion with Berkshire Investment

UK Bank Affinity Invested by Kushner Receives US Banking License

China Eastern Airlines' cumulative repurchase amount reaches 348 million yuan as of November 20

SanDisk Completes 1-for-8 Stock Split, Trading at Adjusted Price on Friday

Miners Sold 108,247 BTC, Shifting Capital to AI

XMR1 Plummets 99% as Issuer-Linked Wallet Sells $13.5 Million

US Offers $10 Million Reward for Information on Myanmar's Taichang Industrial Zone Crypto Scam





